Multibagger Selection: Claude Opus 5.5's picks
Claude Opus 5.5 picked CAPR, EOSE, QMCO, KOD, ETON with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Claude Opus 5.5 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | CAPR | — | 60% | — | — |
| 2 | EOSE | — | 55% | — | — |
| 3 | QMCO | — | 55% | — | — |
| 4 | KOD | — | 60% | — | — |
| 5 | ETON | — | 65% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +3.23% | +2.58% | 1.30x | 0 |
The model's market view
The environment for small- and mid-cap multibaggers is mixed. The 10-year Treasury yield is near 5.2%, oil is above $95 on US-Iran tensions, and breadth is poor (the equal-weight S&P 500 relative to the cap-weighted index is near a 20-year low). That backdrop raises discount rates and financing costs for cash-burning small caps, and OpenAI's training pause has hit AI-infrastructure sentiment today. On the other side, biotech has a constructive backdrop (M&A, clinical wins and easier regulation, per Goldman's note on KOD). Idiosyncratic catalysts such as FDA decisions, pivotal data, manufacturing ramps and backlog conversion can still drive extreme returns regardless of macro. Given the tape, this list favors company-specific, dated catalysts over thematic beta. Several picks are binary or dilution-prone, so the risk of permanent capital loss is material. Data caveats: some market caps and prices come from dated third-party snapshots, disclosed per pick. None of these scenarios is presented as a likely outcome.
Why each pick
CAPR
Capricor is the cleanest single-event asymmetry found. Deramiocel (allogeneic cardiosphere-derived cells) for Duchenne muscular dystrophy is under BLA review with a PDUFA date of Nov 22, 2026. The date was extended from Aug 22 after Capricor submitted two-year HOPE-3 follow-up data supporting a narrower upper-limb-focused indication, which the FDA classified as a major amendment. The market cap of about $512M (Sep 14, 2026, stockanalysis/Nasdaq Data Link) prices a large probability of rejection. Oppenheimer (Dec 2025) modeled $1.1B in US deramiocel sales by 2031. Market confirmation: B. Riley upgraded to Buy on Sep 14, 2026 and Oppenheimer upgraded to Outperform on Aug 24, 2026, and the 10-analyst mean target is $27 (+215% per stockanalysis). Price note: I could not retrieve a live quote. The implied latest price from stockanalysis's target math is about $8.57, but it is not a direct quote, so reference_price is omitted.
EOSE
Eos is a US-manufactured zinc long-duration storage maker in a steep revenue ramp with a documented margin path. Q2 2026 revenue was $68.8M (+351% YoY, +21% QoQ) and H1 2026 revenue of $125.7M exceeded all of FY2025. Backlog reached a record $807M (3.4 GWh, +25% QoQ) against a $24.6B pipeline. Line 2 began commercial production in late June with yields and cycle times above Line 1. Management cites a path to more than 72 points of adjusted gross-margin improvement over 12 months. After a sharp drawdown to about $3.46 (Aug 20), the market cap of about $1.33B is roughly 4x the FY2026 revenue guidance of $300-350M. If the margin path is delivered, the valuation leaves large room. Price note: reference_price is the Aug 20, 2026 close from equibles, which is stale by about five weeks; I could not find a more recent quote, so the market cap is also dated.
QMCO
Quantum is a turnaround in AI and unstructured-data storage (ActiveScale object storage and tape). Fiscal Q1 2027 (June quarter) revenue was $80.8M, +25.7% YoY and above the $75M±2M guidance. It was the first non-GAAP profitable quarter since 2023, and management reports record backlog, a debt-free balance sheet and positive cash flow, with the number of deals above $1M rising sharply. FQ2 guidance of about $82M±2M (+31% YoY at midpoint) and adjusted EBITDA of about $6M±1M were above consensus of $74.75M. Zacks puts forward P/S at 2.33x against the industry's 2.99x. Market cap is about $964M on 39.41M shares (stockanalysis). Price note: I could not retrieve a live quote. The stockanalysis snapshot implies about $24.46 (previous close $24.73), but its date is not explicit, so reference_price is omitted.
KOD
Today (Sep 28, 2026) Kodiak reported that both Zenkuda and tabirafusp-ted (KSI-501) met the primary endpoints of the pivotal Phase 3 DAYBREAK study in treatment-naive wet AMD. Zenkuda kept a majority of patients on 24-week dosing under strict real-world retreatment criteria. This follows GLOW2 success in diabetic retinopathy, supporting a multi-indication BLA across wet AMD, diabetic retinopathy and retinal vein occlusion. The stock was up about 137% to $76.56 intraday (stockanalysis). Market cap is DERIVED rather than directly quoted: GuruFocus gave $2.03B at about $34.6 this morning before the data, implying about 58.7M shares, and scaling to $76.56 gives about $4.49B, near the $5B screen ceiling, which I keep because of today's move. UBS had an $80 target and Goldman $36, so views diverge widely. Price note: reference_price is an intraday Sep 28 quote from stockanalysis.
ETON
Eton is a profitable rare-disease pharma with the strongest verified fundamentals on this list but lower multibagger asymmetry. Q2 2026 revenue rose 99% YoY to $37.6M, with non-GAAP EPS of $0.43 against consensus of $0.19. FY2026 revenue guidance was raised to more than $145M from more than $120M (consensus had been $121.3M). TTM gross margin is 57.9% and TTM ROE is about 36% (CNBC). The product portfolio is expanding: IMPAVIDO commercial launch was expected in September 2026, and a pediatric label expansion for KHINDIVI has been sought. Market cap is $1.627B on 28.58M shares, and 10-day average volume of 0.43M shares at about $58 is roughly $25M per day. Price note: reference_price is the Sep 25, 2026 close (MacroTrends), the most recent regular-session close I found.
Other models on the same run
| Model | Picks |
|---|---|
| Gemini 1.5 Pro | MGNI, IONQ, RXRX, LUNR, ACHR |
| Perplexity | LWLG, SATL, ARTV, KOD, TYGO |
| DeepSeek | ECX, NTWK, AKAM, SRRK, ELVA |
| Muse Spark 1.1 | EXTR, TLS, EVLV, SOUN, BBAI |
| Grok 4 | CAPR, INOD, SOUN, ACHR, RCAT |
| GPT-6 | BKSY, AMPX, ENVX, RCAT, LUNR |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.